Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Source ↗
👁 0
💬 0
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
Comments (0)